| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/26/2013 | US8404703 Medicinal compositions containing aspirin |
| 03/26/2013 | US8404681 Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
| 03/26/2013 | US8404665 In vivo use of glutathione S-transferase activated nitric oxide donors |
| 03/26/2013 | US8404249 Polylysine positively charged backbone, oligoarginine branching group, hydroxypropylcellulose viscosity modifying agent; treat wrinkles, hyperhidrosis, neurologic pain, migraine headache, reducing muscle spasms, preventing or reducing acne |
| 03/26/2013 | US8404226 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 03/26/2013 | CA2565295C Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 03/26/2013 | CA2537820C Process for preparing water-soluble medicaments comprising complexation of forskolin in cyclodextrins |
| 03/26/2013 | CA2513773C Clindamycin phosphate foam |
| 03/26/2013 | CA2474424C Salts of valsartan |
| 03/26/2013 | CA2463850C Remodeling of tissues and organs |
| 03/26/2013 | CA2356621C Assay for identifying compounds which affect stability of mrna |
| 03/21/2013 | WO2013040568A1 Methods for treating hcv |
| 03/21/2013 | WO2013040265A1 Compositions for treating bone diseases and broken bones |
| 03/21/2013 | WO2013039989A1 Particluate vaccine formulations |
| 03/21/2013 | WO2013039916A1 Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| 03/21/2013 | WO2013039197A1 IκB KINASE α ACTIVATION INHIBITOR |
| 03/21/2013 | WO2013038740A1 Method for screening for substance or factor capable of promoting muscle hypertrophy |
| 03/21/2013 | WO2013038666A1 Light-induced seizure model in rat brains |
| 03/21/2013 | WO2013037943A1 Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors |
| 03/21/2013 | WO2013037713A1 Combinations comprising a s1p receptor modulator |
| 03/21/2013 | WO2013037129A1 Antitumour pharmaceutical composition with two active components and use thereof |
| 03/21/2013 | US20130072553 Drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor |
| 03/21/2013 | US20130072550 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 03/21/2013 | US20130072484 Tyrosine kinase inhibitors as anti-kinetoplastid and anti-apicomplexan agents |
| 03/21/2013 | US20130072474 Treatment of dementia of alzheimer's type with masitinib |
| 03/21/2013 | US20130072460 Methods Of Treating Retroviral Infections And Related Dosage Regimes |
| 03/21/2013 | US20130072441 Protease Inhibitors and Preventives or Remedies for Disease |
| 03/21/2013 | US20130072427 Gpr 119 modulators |
| 03/21/2013 | US20130071496 Controlled release composition containing a strontium salt |
| 03/21/2013 | US20130071486 Acellular tissue matrices made from alpha-1,3-galactose-deficient tissue |
| 03/21/2013 | US20130071442 Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections |
| 03/21/2013 | US20130071407 Methods for modulating hematopoiesis and vascular growth |
| 03/21/2013 | US20130071394 Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use |
| 03/21/2013 | US20130071376 Bathing composition and method for preparing same |
| 03/21/2013 | US20130071350 Method and compositions for treatment of cancers |
| 03/21/2013 | US20130071320 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 03/21/2013 | DE102011114094A1 Stimulierendes und belebendes Nasenspray und Nasentropfen Stimulating and invigorating nasal spray and nasal drops |
| 03/21/2013 | DE102011082871A1 Use of an active agent that inhibits or activates a gene e.g. ubiquitin specific peptidase 18 for preventing and treating autoimmune, inflammatory and immune disorders e.g. acute hepatitis, malaria, HIV infection, rabies or osteoarthritis |
| 03/21/2013 | CA2852989A1 Compositions for treating bone diseases and broken bones |
| 03/21/2013 | CA2847355A1 Methods for treating hcv |
| 03/21/2013 | CA2847091A1 Compositions and methods for treating cancer using pi3k.beta. inhibitor and mapk pathway inhibitor, including mek and raf inhibitors |
| 03/21/2013 | CA2846768A1 Combinations comprising a s1p receptor modulator |
| 03/20/2013 | EP2570132A2 Method for preparing novel processed ginseng or an extract thereof, the usually minute ginsenoside content of which is increased |
| 03/20/2013 | EP2570127A1 Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
| 03/20/2013 | EP2569336A1 Enhanced death receptor agonists |
| 03/20/2013 | EP2568992A2 Pharmaceutical composition comprising an algae adapted to increase the efficacy of an enzymatic inhibitor |
| 03/20/2013 | EP2568978A2 Cancer prevention and treatment methods based on dietary polyamine content |
| 03/20/2013 | EP2568972A2 Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbesartan |
| 03/20/2013 | EP2568826A1 Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline |
| 03/20/2013 | CN1441841B Stimulation of cellular regeneration and differentiation in inner ear |
| 03/20/2013 | CN102985112A Pharmaceutical composition for treatment and prevention of herpesvirus infections |
| 03/20/2013 | CN102985089A Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| 03/20/2013 | CN102977384A Modification method and application of cellulosa-imitating film structure of polylactic acid nano-particle surface |
| 03/20/2013 | CN102973947A Antibody-drug conjugates and methods |
| 03/20/2013 | CN102973942A Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors |
| 03/20/2013 | CN102973941A Polymer hydrogel loading chemotherapy drug, and application thereof in preventing tumor recurrence and preventing and treating postoperative abdominal adhesion |
| 03/20/2013 | CN102973940A Pharmaceutical composition for inhibiting or killing helicobacter pylori and use thereof |
| 03/20/2013 | CN102973928A Compositions and methods for priming monocytic dendritic cells and T cells for TH-1 response |
| 03/20/2013 | CN102973542A Micromolecular substance for improving sensitivity of bacteria to antibiotics |
| 03/20/2013 | CN102973417A Pharmaceutical and cosmetic compositions containing oxy group-bearing aromatic aldehydes |
| 03/20/2013 | CN102065865B Multiple myeloma treatments |
| 03/20/2013 | CN101951922B Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 03/20/2013 | CN101677978B Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor |
| 03/20/2013 | CN101583357B Use of MTOR antagonist and angiogenesis inhibitor for preparing medicine for treating cancer |
| 03/20/2013 | CN101478956B Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
| 03/19/2013 | US8399650 Mycobacterial antigens expressed during latency |
| 03/19/2013 | US8399617 Non-functional P2X7 receptor |
| 03/19/2013 | US8398997 Polylysine positively charged backbone, oligoarginine branching group, hydroxypropylcellulose viscosity modifying agent; treating wrinkles, hyperhidrosis, neurologic pain, migraine headache, reducing muscle spasms, preventing or reducing acne |
| 03/19/2013 | US8398992 Methods and compositions for polytopic vaccination |
| 03/19/2013 | US8398990 Glucan-based vaccines |
| 03/19/2013 | US8398984 Removal promoters and inhibitor for apoptosis cells in vivo |
| 03/19/2013 | CA2513251C Cancer therapy sensitizer |
| 03/19/2013 | CA2488499C Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 03/19/2013 | CA2429342C Promoters exhibiting endothelial cell specificity and methods of using same |
| 03/14/2013 | WO2013035861A1 Method for determining susceptibility to age-related macular degeneration, primer pair, probe, age-related macular degeneration diagnostic kit, therapeutic agent for age-related macular degeneration, and screening method for therapeutic agent for age-related macular degeneration |
| 03/14/2013 | WO2013035779A1 Method of analysis of intercell interactions |
| 03/14/2013 | WO2013035757A1 Preparation comprising hexose-6-phosphate-modified cholesterol derivative |
| 03/14/2013 | WO2013035209A1 Method of applying etfb to abnormal proliferation of cell, and abnormal proliferation inhibitor |
| 03/14/2013 | WO2013035208A1 ANTIBODY AGAINST MUTANT α-ACTININ-4 |
| 03/14/2013 | US20130066052 Ucp4 |
| 03/14/2013 | US20130065961 Modulation of physiological processes and agents useful for same |
| 03/14/2013 | US20130065869 Ophthalmologic irrigation solutions and method |
| 03/14/2013 | US20130064877 Composition for the transdermal delivery of fentanyl |
| 03/14/2013 | US20130064760 Method for Treating Crohn's Disease By Administering An Anti-IL-12 Antibody |
| 03/13/2013 | EP2567956A1 Novel prenylarene compound and use thereof |
| 03/13/2013 | EP2567705A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 03/13/2013 | EP2567701A2 Treatment of heart failure in non-human mammals with an aldosterone antagonist |
| 03/13/2013 | EP2566878A1 Methods of inhibiting inflammation and inflammatory diseases using gal-3bp (btbd17b, lgals3bp, galectin-3 binding protein, mac-2 binding protein) |
| 03/13/2013 | EP2566476A1 Nicotine-containing pharmaceutical compositions |
| 03/13/2013 | EP2566465A2 Stable rosuvastatin formulations |
| 03/13/2013 | EP1962903B1 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer |
| 03/13/2013 | EP1392359B2 Specific binding proteins and uses thereof |
| 03/13/2013 | CN102971318A Tetrahydrocarboline derivative |
| 03/13/2013 | CN102971003A Improved cancer therapy based on tumor associated antigens derived from cyclin D1 |
| 03/13/2013 | CN102965425A Medicament screening method, medicament used for promoting crosslink of extracellular matrix and application of medicament |
| 03/13/2013 | CN102964239A Metallo-beta-lactamase inhibitor |
| 03/13/2013 | CN102961756A Synthesis method of polypeptide-nanogold particle drug carrier |
| 03/13/2013 | CN102961755A Ligand-functioned super-molecular nano-drug delivery system for treating tumor |
| 03/13/2013 | CN102961751A Composition for improving oral bioavailability of alkaloid and preparation method |
| 03/13/2013 | CN102961749A Application of fibrate drugs used as drugs for inhibiting myopia |